Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STRIDE: Siplizumab in New Onset Type 1 Diabetes
2022-001713-39Phase 2Active
- Sponsor
- ITB-MED
- Start
- Jun 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial in diabetes mellitus type 1 (T1D) comparing Siplizumab with Placebo (2 arms). Primary endpoint: Change in 4-hour stimulated C-peptide AUC. Started Jun 2022; status: active.
02
Drugs
siplizumab
03
Conditions
diabetes mellitus type 1 (T1D)
Beyond the preview
Go deeper on 2022-001713-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-001713-39.